研究者詳細 - 長尾　昌二

MISC - 長尾　昌二

分割表示 131 件中 61 - 80 件目／全件表示 >>

Intravenous/Intraperitoneal Paclitaxel and Intraperitoneal Carboplatin in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma A Feasibility Study 国際誌

Shoji Nagao, Norihiro Iwasa, Akira Kurosaki, Tadaaki Nishikawa, Rie Ohishi, Kosei Hasegawa, Tomoko Goto, Keiichi Fujiwara

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 22 ( 1 ) 70 - 75 2012年1月

記述言語：英語出版者・発行元：LIPPINCOTT WILLIAMS & WILKINS

Objective: This study aimed to evaluate intravenous (IV)/intraperitoneal (IP) paclitaxel and IP carboplatin (TCipTip therapy) feasibility in epithelial ovarian (EOC), fallopian tube (FTC), or peritoneal carcinoma (PC) patients.
Methods: From December 2007 to August 2010, 20 women with histologically confirmed stage IC to IV EOC, FTC, or PC received 6 TCipTip cycles after the primary cytoreductive surgery. Intravenous paclitaxel was administered at 135 mg/m(2) followed by IP carboplatin based on the area under the curve = 6 on day 1; IP paclitaxel at 60 mg/m2 was administered on day 8. The toxicity grade was determined by CTCAE version 3.0. The institutional review board requested we reduce the IP paclitaxel dose in the first cycle to ensure safety.
Results: Twenty women, including 18 with EOC, 1 with stage IIC FTC, and 1 with stage IV primary PC, received TCipTip therapy. There were 12 serous, 5 endometrioid, 1 mucinous, 1 clear cell adenocarcinoma, and 1 mixed carcinoma (clear cell and endometrioid) cases. Eleven women achieved optimal status at primary surgery. Grade 3/4 hematologic toxicity incidence was 73% (neutrocytopenia), 9% (thrombocytopenia), and 24% (anemia). Grade 3/4 nonhematologic toxicities were observed in 5 patients (4 with grade 3 allergy and 1 with grade 3 ileus). Twelve patients (60%) completed more than 6 chemotherapy cycles. Reasons for interruption included paclitaxel allergy, grade 2 abdominal pain, carboplatin allergy during the seventh cycle, disease progression, pleural embolism, ileus, and address change.
Conclusions: Toxicities for TCipTip therapy were acceptable; this therapy is feasible for EOC, FTC, or PC patients. Further TCipTip therapy evaluation is warranted.

DOI： 10.1097/IGC.0b013e318234f927

Web of Science

PubMed

researchmap

Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer. 国際誌

20 ( 9 ) 1563 - 8 2011年10月

腹腔内化学療法 (今月の臨床卵巣がん--最新の治療戦略) -- (初回治療--ファーストラインの化学療法)

藤原恵一, 岩佐紀宏, 長尾昌二

臨床婦人科産科 65 ( 7 ) 891 - 896 2011年7月

Taxane系薬剤のIP/IV投与モデル

宮木康成, 藤原恵一, 宮木裕司, 小田隆司, 長尾昌二, 伊藤潔, 高野忠夫, 八重樫伸生, 山口万紀子, 高田智价, 清川麻知子, 堀本直幹, 橋本雅, 三宅馨

日本婦人科腫瘍学会雑誌 29 ( 3 ) 530 - 530 2011年6月

Supportive care for hand-foot syndrome and stomatitis in relapsed ovarian cancer patients receiving pegylated liposomal doxorubicin.

M. Shimada, S. Sato, T. Otsuki, T. Takano, N. Yaegashi, H. Fujiwara, M. Suzuki, S. Nagao, K. Fujiwara, Y. Yokoyama, H. Mizunuma, S. Kumagai, T. Sugiyama, H. Kurachi, K. Takizawa, M. Hiura, H. Yoshikawa, K. Takehara, K. Ochiai, J. Kigawa

JOURNAL OF CLINICAL ONCOLOGY 29 ( 15 ) 2011年5月

Development of a mathematical model of intraperitoneal/intravenous infusion of taxanes.

Y. Miyagi, K. Fujiwara, K. Ito, Y. Miyagi, T. Takano, S. Nagao, N. Yaegashi, T. Oda, T. Miyake, K. Miyake

JOURNAL OF CLINICAL ONCOLOGY 29 ( 15 ) 2011年5月

卵巣がんの薬物療法腹腔内化学療法（IP療法）

臨床腫瘍プラクティス 2011年4月

がん性腹膜炎

産科と婦人科 2011年3月

A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer 国際誌

Keiichi Fujiwara, Eriko Aotani, Tetsutaro Hamano, Shoji Nagao, Hiroyuki Yoshikawa, Toru Sugiyama, Junzo Kigawa, Daisuke Aoki, Noriyuki Katsumata, Masahiro Takeuchi, Mitsuaki Suzuki

JAPANESE JOURNAL OF CLINICAL ONCOLOGY 41 ( 2 ) 278 - 282 2011年2月

記述言語：英語出版者・発行元：OXFORD UNIV PRESS

Retrospective studies and a Phase II trial demonstrated the promising efficacy and safety of intraperitoneal administration of carboplatin in ovarian, fallopian tube and primary peritoneal cancer. A Japanese Gynecologic Oncology Group 3016 randomized Phase III trial for these cancers showed dose-dense weekly administration of paclitaxel significant improvement of progression-free survival and overall survival over every 3-week administration. From June 2010, we have been conducting a randomized Phase II/III trial of intravenous versus intraperitoneal administration of carboplatin every 3 week in combination with dose-dense weekly administration of paclitaxel. The purpose of this trial is to prove the superiority of intraperitoneal administration of carboplatin over intravenous administration. Primary endpoint is progression-free survival and secondary endpoints include overall survival, quality of life assessment and cost-benefit. The first 120 patients will be evaluated for the feasibility of intraperitoneal arm and a total of 746 patients will be enrolled in a Phase III study.

DOI： 10.1093/jjco/hyq182

Web of Science

PubMed

researchmap

卵巣がんIa期および境界悪性腫瘍における妊孕能温存治療

産婦人科の実際 2011年2月

再発卵巣癌に対するリポソーマルドキソルビシン単剤療法における手足症候群および口内炎予防のためのサポーティブケアに関する多施設共同研究

島田宗昭, 紀川純三, 佐藤慎也, 八重樫伸生, 高野忠夫, 大槻健郎, 鈴木光明, 藤原寛行, 藤原恵一, 長尾昌二, 水沼英樹, 横山良仁, 倉智博久, 中原健次, 杉山徹, 熊谷晴介, 滝澤憲, 岩瀬春子, 竹原和宏, 中村紘子, 日浦昌道, 白山裕子, 吉川裕之, 佐藤豊実, 落合和徳, 山田恭輔, 波多江正紀, 中村俊昭

日本産科婦人科学会雑誌 63 ( 2 ) 868 - 868 2011年2月

卵巣がん1a期および境界悪性腫瘍における妊孕性温存治療 (特集婦人科がん妊孕性・卵巣機能温存治療と妊娠・分娩)

長尾昌二, 西川忠暁, 黒崎亮

産婦人科の実際 60 ( 2 ) 181 - 187 2011年2月

P2-28-3 当科で行った腹腔内化学療法におけるIntraperitoneal Port System(IPS)関連合併症の検討(Group130 婦人科悪性腫瘍・その他,一般演題,第63回日本産科婦人科学会学術講演会)

大石理恵, 長尾昌二, 鈴木裕之, 佐藤加寿子, 黒崎亮, 岩佐紀宏, 長谷川幸清, 藤原恵一

日本産科婦人科學會雜誌 63 ( 2 ) 888 - 888 2011年

腹腔内化学療法の現状と将来展望 (特集卵巣がんに関する最新トピックス)

長尾昌二, 祖川侑子, 水上順智

産婦人科の実際 59 ( 10 ) 1519 - 1525 2010年10月

ASSESSMENT OF SUPPORTIVE CARE FOR HAND-FOOT SYNDROME AND STOMATITIS IN RELAPSED OVARIAN CANCER PATIENTS RECEIVING PEGYLATED LIPOSOMAL DOXORUBICIN

T. Otsuki, N. Yaegashi, M. Shimada, S. Nagao, M. Suzuki, H. Mizunuma, H. Kurachi, T. Sugiyama, K. Takizawa, J. Kigawa

ANNALS OF ONCOLOGY 21 388 - 389 2010年10月

Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers

Tomoko Goto, Masashi Takano, Rie Ohishi, Norihiro Iwasa, Motohiro Shimizu, Kosei Hasegawa, Shoji Nagao, Keiichi Fujiwara

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH 36 ( 4 ) 764 - 768 2010年8月

記述言語：英語出版者・発行元：WILEY-BLACKWELL PUBLISHING, INC

Aim:
To evaluate toxicity, response and progression-free survival of single nedaplatin chemotherapy in women with platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancer.
Methods:
Seventeen patients with platinum/taxane-resistant/refractory epithelial ovarian, fallopian tube or primary peritoneal cancer who were treated with a single nedaplatin regimen at 90 mg/m2 administration on day 1 of a 28-day cycle in our institution between 2005 and 2007 were retrospectively investigated.
Results:
Ten of 17 patients (59%) had measurable disease. Seven patients were evaluated according to cancer antigen (CA) 125 levels. The overall response was 24% (complete response, 2 patients; partial response, 2 patients). Two of these 4 patients had measurable disease. Stable disease and progressive disease was noted in 6 (35%) and 7 (41%) patients. Median progression-free survival was 8 months (range 3-11) in patients who responded to therapy and 4 months (range 2-6) in patients with stable disease. Mean platinum-free interval due to treatment without using platinum analogues after developing platinum-resistant/refractory disease was 11 months (range 8-12) in patients who responded to nedaplatin regimen and 3 months (range 1-11) in patients who did not (P < 0.01), whereas mean treatment-free interval was 3 months (range 1-5) in responders and 1 month (range 1-3) in non-responders, which did not show a significant difference. Grade 4 hematological toxicity was observed in 2 of 17 patients (12%). No grade 3 or 4 non-hematological toxicity occurred. All toxicities were managed on an outpatient basis.
Conclusions:
Single nedaplatin treatment for platinum/taxane-resistant/refractory ovarian, tubal and peritoneal cancer patients is the candidate of salvage chemotherapy with comparable effectiveness and less toxicity to other approved regimens.

DOI： 10.1111/j.1447-0756.2010.01217.x

Web of Science

researchmap

Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers 国際誌

Tomoko Goto, Masashi Takano, Rie Ohishi, Norihiro Iwasa, Motohiro Shimizu, Kosei Hasegawa, Shoji Nagao, Keiichi Fujiwara

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH 36 ( 4 ) 764 - 768 2010年8月

記述言語：英語出版者・発行元：WILEY-BLACKWELL PUBLISHING, INC

DOI： 10.1111/j.1447-0756.2010.01217.x

Web of Science

PubMed

researchmap

少量の Paclitaxel を併用した Carboplatin 療法の検討